U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

On April 28, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Prudential Financial Declares Quarterly Dividend on Common Stock

Textron Aviation and TAM celebrate 40-years of offering world-class aircraft and support in Brazil during LABACE 2022; King Air 360 makes show debut

Brandi Carlile Launches Exclusive Siriusxm Show ‘somewhere Over the Radio’ on the Spectrum (Ch. 28)